NCT01045317View on ClinicalTrials.gov

A Study To Investigate The Clearance Of PF-04776548 From The Body Following A Very Low (Micro) Dose Of The Compound Using A Low Level Of Radiotracer To Help Quantify Expected Low Concentrations Of PF-04776548 In The Body

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Human Immunodeficiency Virus (HIV)
Interventions
DRUG

PF-04776548

single intravenous or oral administration of 0.1mg PF-04776548.

Trial Locations (1)

NG11 6JS

Pfizer Investigational Site, Ruddington Fields

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01045317 - A Study To Investigate The Clearance Of PF-04776548 From The Body Following A Very Low (Micro) Dose Of The Compound Using A Low Level Of Radiotracer To Help Quantify Expected Low Concentrations Of PF-04776548 In The Body | Biotech Hunter | Biotech Hunter